menu_open Columnists
Kanishka Das

Kanishka Das

Quartz

We use cookies to provide some features and experiences in QOSHE

More information  .  Close

MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE

Merck is expanding its pipeline and newer drug portfolio to offset Keytruda's 2028 LOE and drive long-term growth.

11.09.2026 10

Quartz

Kanishka Das

Can MRK's Ongoing M&A Push Aid Long-Term Growth Ahead of Keytruda LOE?

Merck's recent M&A spree, including its $6.7B Terns deal, aims to diversify its pipeline and revenue base as Keytruda nears its 2028 exclusivity loss.

31.03.2026 20

Quartz

Kanishka das